EV-to-Revenue is calculated as enterprise value divided by its revenue. As of today, Nova Eye Medical's enterprise value is $44.28 Mil.
Nova Eye Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $12.58 Mil. Therefore, Nova Eye Medical's EV-to-Revenue for today is 3.52.
The historical rank and industry rank for Nova Eye Medical's EV-to-Revenue or its related term are showing as below:
ELXMF'
s EV-to-Revenue Range Over the Past 10 Years
Min: -3.86 Med: 1.13 Max: 3.88
Current: 2.73
During the past 13 years, the highest EV-to-Revenue of Nova Eye Medical was 3.88. The lowest was -3.86. And the median was 1.13.
ELXMF's EV-to-Revenue is ranked worse than 51.2% of 830
companies
in the Medical Devices & Instruments industry
Industry Median: 3.265
vs ELXMF: 2.73
As of today (2024-05-22), Nova Eye Medical's stock price is $0.10.
Nova Eye Medical's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 was $0.07. Therefore, Nova Eye Medical's PS Ratio for today is 1.45.
Nova Eye Medical EV-to-Revenue Historical Data
The historical data trend for Nova Eye Medical's EV-to-Revenue can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Nova Eye Medical's EV-to-Revenue
For the Medical Devices subindustry, Nova Eye Medical's EV-to-Revenue, along with its competitors' market caps and EV-to-Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Nova Eye Medical's EV-to-Revenue Distribution in the Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Nova Eye Medical's EV-to-Revenue distribution charts can be found below:
* The bar in red indicates where Nova Eye Medical's EV-to-Revenue falls into.
Nova Eye Medical's current Enterprise Value is $44.28 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Nova Eye Medical's Revenue for the trailing twelve months (TTM) ended in Dec. 2023 was $12.58 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical (OTCPK:ELXMF) EV-to-Revenue Explanation
Nova Eye Medical's share price for today is $0.10.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. {COMPANY->company}'s Revenue per Sharefor the trailing twelve months (TTM) ended in Dec. 2023 was $0.07.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Nova Eye Medical EV-to-Revenue Related Terms
Thank you for viewing the detailed overview of Nova Eye Medical's EV-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.
Nova Eye Medical (Nova Eye Medical) Business Description
Nova Eye Medical Ltd is a medical technology company that develops, manufactures and sells a portfolio of proprietary ophthalmic treatment technologies and devices. Used by eye surgeons globally, these technologies include iTrack minimally invasive glaucoma surgery (MIGS), a consumable surgical device that restores the eye's natural outflow pathway to lower pressure inside the eye and to eliminate patient reliance on anti-glaucoma medications for mild-moderate glaucoma. The company's operating segment include AlphaRET and Glaucoma Surgical Devices, it generates maximum revenue from Glaucoma Surgical Devices. Geographically, it derives a majority of revenue from the United States of America.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
ELXMF has been successfully added to your 